Cheryl Guttman Krader, BS, Pharm

Speaking at AAO 2019, Ashraf El Habbak MD, PhD pointed out that bevacizumab inhibits vascular endothelial growth factor, which is a potent permeability factor implicated in cystoid macular edema.

According to William D. Trattler, MD, surgeons today can choose from a number of newer modalities that address the drawbacks associated with previous options.

According to Jeffrey Heier, MD, RGX-314 administered by subretinal injection was well tolerated. In addition, it was associated with dose-dependent increase in ocular protein expression and evidence of clinical benefit.

Nieraj Jain, MD, describes the investigations that led to the recent identification of this drug-related retinal toxicity and described the clinical features that support its diagnosis.

Speakers at AAO 2019 event describe journey leading to approval of the first gene therapy for a genetic disease.

Researchers demonstrate the feasibility of a surgical method that specifically targets the area of geographic atrophy for RPE replacement.

The transzonular injection of a corticosteroid and fluoroquinolone can prevent postoperative infection and inflammation.

Phase III studies of a gene therapy for Leber Hereditary Optic Neuropathy have generated some unexpected positive findings. There is biologic plausibility to explain the data.

Tools for higher-order OCT assessment enable evaluation of features of interest, such as targeted retinal layers or fluid compartments, and may allow for unique characterization of disease phenotypes and treatment response.

The results of the phase II FILLY study are in agreement with the prior literature on risk factors for GA progression.